Pregabalin

Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes

...ut 20 percent more than did a placebo agent. Thus, pregabalin appears to offer about the same benefit as gabapen...not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option," says the ...logist at the Mayo Clinic in Minnesota. While pregabalin offers about the same benefit as gabapentin, women...

Mayo Clinic researchers say agent provides treatment option for women with hot flashes

...ut 20 percent more than did a placebo agent. Thus, pregabalin appears to offer about the same benefit as gabapen...not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option," says the ...ologist at the Mayo Clinic in Minnesota. While pregabalin offers about the same benefit as gabapentin, women...

New Treatment Discovered for Restless Legs Syndrome Improves Sleep

...ith RLS. Of the group, 30 people received the drug pregabalin and the rest received placebo. Sleep studies were...ers found nearly two-thirds of the people who took pregabalin had no RLS symptoms while taking the drug. For peo...tute in Madrid, Spain. "However, our findings show pregabalin helped people get more deep sleep. The drug was we...

FDA Advisers Don't Back 'Black Box' Warning for Epilepsy Drugs

...l), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), Levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depa...

FDA Advisers Don't Back Epilepsy Drug Warnings

...l), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), Levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depa...

Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds

...l), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), Levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depa...

FDA Warns Epilepsy Drugs May Raise Suicide Risk

...l), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), Levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depa...

Anti-Convulsant Aids Knee-Replacement Patients

... pregabalin reduced pain, increased range of motion, study fou...o two groups. One group received 300 milligrams of pregabalin two hours before surgery and 150 mg twice a day fo... the 32 hours after surgery, patients who received pregabalin reported lower levels of pain and used less pain m...

Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best

...in the 1990s. These include gabapentin (Neurontin), lamotrigine (Lamictal), pregabalin (Lyrica) and topiramate (Topamax). Both the old and new anticonvulsants -...ve pain associated with diabetes or herpes zoster infection (shingles) -- pregabalin (Lyrica) -- for treating the nerve pain associated with diabetes or herpes ...

Pregabalin Proves Durable Pain Relief Option for Fibromyalgia

...-week program of 300, 450 or 600 mg daily doses of pregabalin to optimize pain control and medication tolerance....nto a 26-week double-blind study to receive either pregabalin at the optimal dosage established during the 6 wee...nts on medication. The most common side effects of pregabalin were dizziness, somnolence, sinusitis, joint pain ...

Pregabalin in Biological Technology

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

...eceptor agonist (GW/Bayer), and fentanyl buccal (Cephalon). Eighteen drugs are in Phase III development in the US including two GABA receptor agonists pregabalin (Pfizer) and gabapentin GR (Depomed); a sodium channel antagonist mexiletine (Boehringer Ingelheim); three glutamate / NMDA antagonists ketamine intra...